---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-037345"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:59:25.077601+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius raises ~$15M via registered direct offering of 12.5M shares and warrants

## Summary
- Issued 12.5M shares and warrants to purchase 12.5M shares at $1.20/unit in registered direct offering.
- Gross proceeds ~$15M; net proceeds for general corporate purposes, including clinical development.
- Warrants have exercise price $1.50, exercisable six months after issuance, expire in five years.
- H.C. Wainwright acted as placement agent; cash fee ~$1.05M plus expenses and placement agent warrants.
- Offering closed May 8, 2023; 60-day lock-up on further equity issuance and one-year restriction on floating-price securities.

## SEC filing metadata
- accession: 0001213900-23-037345
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/0001213900-23-037345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/ea178024-8k_citiuspharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-037345
- JSON: https://secwatch.observer/filing/0001213900-23-037345.json
- Plain text: https://secwatch.observer/filing/0001213900-23-037345.txt

## Key facts
- Material Agreements
  Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at combined offering price of $1.20 (effective 2023-05-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: combined offering price of $1.20
  - Effective: 2023-05-03
  source text: On May 3, 2023, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 12,500,001 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 12,500,001 shares of common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/0001213900-23-037345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.